Nateglinide 105816-04-4
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis. Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Pharmacology
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Dosage
Nateglinide is delivered in 60mg & 120mg tablet form.
| Systematic (IUPAC) name: | 3-phenyl-2-[(4-propan-2-ylcyclohexanecarbonyl)amino]propanoic acid |
|---|---|
| Nateglinide CAS number: | 105816-04-4 |
| ATC code: | A10BX03 |
| PubChem: | 60026 |
| DrugBank: | APRD00593 |
| Formula: | C19H27N1O3 |
| Molecular mass: | 317.423 g/mol |
| Nateglinide Assay/Purity: | Typically NLT 98% |
